Case – Prostate-specific antigen bounce: A pitfall in prostate-specific membrane antigen positron emission tomography/computed tomography interpretation

Pedro, Victor P.; Sistani, Golmehr; Rachinsky, Irina; Zukotynski, Katherine; Liu, Wei

doi:10.5489/cuaj.7257

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Integration of earlier PET-based response assessment, compared to triggered restaging at the time of BF, may provide an opportunity for earlier targeted salvage, but a lack of prospective longitudinal series of men so monitored is a gap in the current evidence base ( 23 ). Indeed, reports of false-positive PET scans in previously treated patients underscore the importance of systematically characterizing the normal patterns of PSMA PET/CT changes after SBRT and their correlation with clinical endpoints ( 48 , 49 ).…”

Section: Introductionmentioning

confidence: 99%

Imaging Biomarkers in Prostate Stereotactic Body Radiotherapy: A Review and Clinical Trial Protocol

et al. 2022

Self Cite

View full text Add to dashboard Cite

Advances in imaging have changed prostate radiotherapy through improved biochemical control from focal boost and improved detection of recurrence. These advances are reviewed in the context of prostate stereotactic body radiation therapy (SBRT) and the ARGOS/CLIMBER trial protocol. ARGOS/CLIMBER will evaluate 1) the safety and feasibility of SBRT with focal boost guided by multiparametric MRI (mpMRI) and 18F-PSMA-1007 PET and 2) imaging and laboratory biomarkers for response to SBRT. To date, response to prostate SBRT is most commonly evaluated using the Phoenix Criteria for biochemical failure. The drawbacks of this approach include lack of lesion identification, a high false-positive rate, and delay in identifying treatment failure. Patients in ARGOS/CLIMBER will receive dynamic 18F-PSMA-1007 PET and mpMRI prior to SBRT for treatment planning and at 6 and 24 months after SBRT to assess response. Imaging findings will be correlated with prostate-specific antigen (PSA) and biopsy results, with the goal of early, non-invasive, and accurate identification of treatment failure.

show abstract

Section: Introductionmentioning

confidence: 99%